The vaccine in India was called Covishield. The vaccine, developed by researchers from Oxford University, can cause Thrombosis with Thrombocytopenia Syndrome (TTS), and the company has admitted ...

British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca has admitted in court papers that its COVID vaccine, Covishield, can cause rare side effect, The Telegraph reported.

The UK's refusal to recognise Covishield had triggered a firestorm of protests in India. With more than 721 million doses administered so far, Covishield is India's primary vaccine. On Tuesday ...

Let’s look at the facts behind the ongoing AstraZeneca (or Covishield, as it is known in India) vaccine controversy, and determine if there really is a cause for worry. Jamie's legal ...

Covishield is now eligible for travel to Austria, Germany, Slovenia, Greece, Ireland and Spain. Iceland and Switzerland too have made the jab eligible for travel to the countries, sources said.

SII makes India's primary COVID-19 vaccine, locally known as Covishield. Poonawalla also revealed that he, along with 7,000 employees of SII, have already taken the third dose of the COVID-19 ...

The first consignment of 4,33,500 doses of Covishield, the vaccine developed by Serum Institute of India against COVID-19, arrived in the State on Wednesday. It was received at the airports with ...

The Nanded-based firm, Cutis-Biotech, in its suit filed on January 4 through advocate Aditya Soni, claimed it has been using the trademark 'Covishield' for its products like antiseptic ...

None of the Covid vaccines originally approved for emergency use completed trial results. Supreme Court should therefore ask ...

The SII is producing two vaccines. The first, Covishield, is one of only a few vaccines approved by the World Health Organization and is based on the COVID vaccine AstraZeneca developed.